Mikhail Blagosklonny’s Peer Review Publication Changes Lives

Mikhail Blagosklonny made Oncotarget to help cancer doctors connect with each other, but it has grown to be so much more than that and it has been helping people with the issues that they are having in different areas. Not only does Oncotarget help Mikhail Blagosklonny learn about the treatment methods that he can try in cancer but it also helps the people who are also in the cancer practice, people who have cancer and students who are learning as much as they can about cancer treatment. Mikhail Blagosklonny is confident in his skills and he knows that he can help other people out with their practices but he also knows that he has a lot to learn from other doctors. He hoped that Oncotarget would be the answer to that and his hopes became a reality because he was able to learn more about cell rejuvenation from the doctors who are a part of the publication.

Some doctors find that they have a hard time connecting with each other. There seems to be a barrier up between different specialists and that can cause a huge problem in the treatment of diseases. Mikhail Blagosklonny knew that if doctors were able to work together, they would be able to make things better for their patients. He saw a lot of value in trying different and unconventional methods so that he could help his patients heal. There have been many options that Mikhail Blagosklonny has added because of Oncotarget and that has allowed him to help other doctors, too.

Perhaps the people who have gained the biggest benefits from Oncotarget are the patients. These are the people who are getting the treatments that the doctors are working on together and that has helped them to feel better. Not only that but they are also able to have a chance at a better life because of the things that are going on in the treatment areas. For Mikhail Blagosklonny to be able to try these things with his patients, he had to make sure that he was learning about them from the people who were publishing them.

Even those who are not doctors yet are able to learn about the treatments and the methods that they will be able to use in the future. Oncotarget is available to students who are researching different specialties. It is something that they have been able to do for a long time and something that Mikhail Blagosklonny is planning to continue. He knows how important it is to help people have a better research experience and knows that students will be able to benefit from all of this because of the way that they can try different things and do more with their careers.

To know more click here

Dr. Clay Siegall Continues To Improve Cancer Treatment

One of the most exciting developments in the fight against cancer in the last few years has been the advancement of targeted therapy drugs. The Seattle-based firm Seattle Genetics founded and led by Dr. Clay Siegall has become an industry leader in this exciting and comparatively new field. The mortality rate has not substantially improved for certain diseases in decades, and Dr. Siegall and his associates at Seattle Genetics are working toward changing that.


What started as a small startup with only a few researchers in 1998 has grown into one of the industry leaders in cancer research. Seattle Genetic has developed the first FDA-approved drug of this type and now has multiple approved applications leading to over 20 partnerships with pharmaceutical companies such as Pfizer, Genentech, and several others. Dr. Siegall is very excited about the future of the company, citing the growing list of new drugs in development stages and the increasing number of potential applications for his existing portfolio. Believing traditional forms of cancer treatment are destined for obscurity and will be replaced with targeted drug therapies as they are more tolerable and much more efficient. Dr. Siegall is confident Seattle Genetics will be a leader in the drug development industry for the 21st century.


Clay Siegall has always been interested in medicine, and the influence technology can have in the treatment of disease. He became interested in cancer treatment while studying zoology at the University of Maryland where he earned a B.S., he also holds a Ph.D. in genetics from George Washington University. While attending the University of Maryland, a member of his family was afflicted with cancer. He soon discovered the treatment was almost worse than cancer itself, the chemotherapy almost caused his family member to die. Other forms of treatment such as radical surgery and amputation convinced him there had to be a better way.


Before founding Seattle Genetics where he is the current CEO Dr. Siegall worked at the Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Siegall left Bristol-Myers for several reasons, he did not like the restraints and felt he was not adequately compensated for the work he was doing. Citing one of his patients, he holds nine, that made Bristol-Myers $80 million and all he saw was a paycheck. Dr. Siegall has authored over 65 scientific articles and serves on the board of three scientific journals.